Will Teva Pharmaceutical Industries LTD Shares Wilt Under the Federal Microscope?

Shares of Teva Pharmaceutical Industries (NYSE: TEVA  ) were down about 1% after the company disclosed a federal investigation into its marketing practices. Both Teva's primary money-maker, Copaxone, which treats multiple sclerosis, and Azilect, used in the treatment of Parkinson's disease, will be the drugs in question during the investigation, which will track events dating back to 2006. If wrongdoing is found, there will probably be a settlement.

In this video, Motley Fool health-care analyst David Williamson notes that while he isn't concerned that this will dramatically affect Teva, such a settlement could come at a crucial time for the company. Paying out billions of dollars in a settlement could seriously affect Teva's flexibility, just as its big earner Copaxone begins facing generic competition. The company is currently trying to get aggressive in the face of this patent cliff, but having this legal issue on the horizon to settle may force the company to keep some of its powder dry at just the wrong time.

What's the best way for investors to play the biotech space?
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2833434, ~/Articles/ArticleHandler.aspx, 9/2/2014 12:29:37 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 3 days ago Sponsored by:
DOW 17,098.45 18.88 0.11%
S&P 500 2,003.37 6.63 0.33%
NASD 4,580.27 0.00 0.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/31/1969 7:00 PM
PATH.DL $0.00 Down +0.00 +0.00%
NuPathe Inc. CAPS Rating: *
TEVA $52.52 Up +0.42 +0.81%
Teva Pharmaceutica… CAPS Rating: ****

Advertisement